
Seaport Therapeutics Publishes Research on Glyph™ Platform’s 55% Lymphatic Drug Absorption
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company specializing in novel neuropsychiatric medicines, has announced the publication of groundbreaking research on its Glyph™ platform. The study, published in Molecular Pharmaceutics, highlights the platform’s unique ability to improve drug…